SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
Sotio agreed to pay Biocytogen up to $325.5 million in upfront and milestone fees for rights to bispecific ADC targeting molecules.
SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
SOTIO Presents Data on SOT201 Immunocytokine at SITC Annual Meeting
Mere days after announcing that trials for its lead IL-15 asset have been halted over poor data, Sotio Biotech has unveiled plans to delve deeper into antibody-drug conjugates (ADCs) courtesy of deal worth $740 million in biobucks.
AMSTERDAM, Oct. 16, 2023 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, enters licensing agreement with SOTIO Biotech (SOTIO), a clinical stage immuno-oncology company owned by PPF Group.
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa
Czech biotech Sotio is immediately scrapping three clinical trials of its interleukin-15 superagonist called nanrilkefusp alfa after interim data showed “insufficient efficacy.”